Qualigen is a biotechnology company focused on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases, as well as the expansion of its flagship FastPack® diagnostic platform.
Vice President, Head of Diagnostics and Corporate Communications
Amy Broidrick
Executive Vice President and Chief Strategy Officer
Christopher L. Lotz
VP and CFO
Michael S. Poirier
Founder President, CEO and Chairman
Shishir Sinha
Senior Vice President and COO
2 past transactions
Nanosynex
Acquisition in 2022
Nanosynex is a diagnostic test that checks bacterial resistance to antibiotics in a record time, using a phenotypic approach that involves microfluidic techniques and fluorescent-based analysis. The test helps doctors determine faster (same-day results) the most appropriate antibiotic treatment for their patients, helping them recover in a shorter time and preventing the spread of resistant bacteria in the environment. By limiting prolonged hospitalization, Nanosynex allows to save significant healthcare costs.
Ritter Pharmaceuticals
Acquisition in 2020
Ritter Pharmaceuticals, Inc. develops novel therapeutic products, which modulate the human gut microbiome to treat inflammatory, gastrointestinal and metabolic diseases. We are discovering a new frontier in human gut health research by exploring the metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into safe and effective applications that can have a meaningful impact on a patient’s health. Our pipeline of novel microbiome modulators selectively increase the growth of beneficial bacteria in the colonic ecosystem and create a meaningful impact on a patient’s health. Our first therapy, RP-G28, is currently under development for the treatment of lactose intolerance and has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease that affects over 1 billion people worldwide. RP-G28 has been studied in a Phase 2 clinical trial and is a first-in-class compound.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.